Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | BRAF | P15056 | 10/20 | 0.34 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | KDM4A | O75164 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
| ▸ | NOS2 | P35228 | 1/20 | 0.33 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.32 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.32 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13666952 | 0.77 | KDM4E (0.42) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9909691 | 0.74 | BRAF (0.35) | BRAFDAOPDE3BPDE3A | |
| SCHEMBL14330156 | 0.74 | AURKA (0.39) | NOS3NOS1NOS2 | |
| SCHEMBL18256847 | 0.74 | KDM4E (0.42) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL9909697 | 0.73 | KDM4E (0.39) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL22210762 | 0.73 | BRAF (0.40) | KDM4EALDH1A1MAPTMEN1KMT2A | |
| SCHEMBL12847025 | 0.73 | DAO (0.35) | HPGDDAOPOLB | |
| SCHEMBL21791187 | 0.72 | ADORA3 (0.42) | KDM4EALDH1A1HPGDHSD17B10 | |
| SCHEMBL10441257 | 0.72 | BRD4 (0.42) | ALDH1A1HSD17B10 | |
| SCHEMBL14327873 | 0.71 | NUDT1 (0.47) | KDM4EALDH1A1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8383816-B2 | Aryl-quinolyl compounds and their use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2013-02-26 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-8198279-B2 | Pyrido[2,3-b]pyrazin-8-substituted compounds and their use | INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE) (GB) | 2012-06-12 | — | — | US | disclosed |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2011-03-03 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298320-A1 | Pyrido[2,3-b]pyrazin-8-substituted Compounds and Their Use | BRAF, NRAS, RAF1 | KDM4E 1437/4885ALDH1A1 1655/4885MAPT 3004/4885 |
| US-20110053946-A1 | Aryl-Quinolyl Compounds and Their Use | BRAF, NRAS, ARAF | KDM4E 791/4885ALDH1A1 1190/4885MAPT 3271/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.